Lucid Diagnostics Inc (LUCD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lucid Diagnostics Inc stock (LUCD) is currently trading at $1.19. Lucid Diagnostics Inc PS ratio (Price-to-Sales) is 37.25. Analyst consensus price target for LUCD is $3.95. WallStSmart rates LUCD as Sell.
- LUCD PE ratio analysis and historical PE chart
- LUCD PS ratio (Price-to-Sales) history and trend
- LUCD intrinsic value — DCF, Graham Number, EPV models
- LUCD stock price prediction 2025 2026 2027 2028 2029 2030
- LUCD fair value vs current price
- LUCD insider transactions and insider buying
- Is LUCD undervalued or overvalued?
- Lucid Diagnostics Inc financial analysis — revenue, earnings, cash flow
- LUCD Piotroski F-Score and Altman Z-Score
- LUCD analyst price target and Smart Rating
Lucid Diagnostics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Lucid Diagnostics Inc (LUCD) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Lucid Diagnostics Inc (LUCD) Key Strengths (0)
Supporting Valuation Data
Lucid Diagnostics Inc (LUCD) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Very expensive at 37.3x annual revenue
Revenue growing slowly at 3.30% annually
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Fairly priced relative to book value
Supporting Valuation Data
Lucid Diagnostics Inc (LUCD) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (37.25), Price/Book (2.16) suggest expensive pricing. Growth concerns include Revenue Growth at 3.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -331.20%, Operating Margin at -971.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -331.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LUCD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LUCD's Price-to-Sales ratio of 37.25x sits near its historical average of 41.04x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 43.21x set in Mar 2026, and 0% above its historical low of 37.25x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~42.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Lucid Diagnostics Inc (LUCD) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Lucid Diagnostics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 4M with 3% growth year-over-year.
Key Findings
Spending 28916% of revenue (1.3B) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Lucid Diagnostics Inc.
Bottom Line
Lucid Diagnostics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Lucid Diagnostics Inc(LUCD)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.